• Publications
  • Influence
Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model
It is indicated that axial, limb and orolingual AIMs possess predictive validity for the preclinical screening of novel antidyskinetic treatments and are suitable for selecting drugs that specifically reduce dyskinesia without diminishing the anti-akinetic effect of L-DOPA. Expand
Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease
It is demonstrated that mGluR5 antagonism produces strong anti‐dyskinetic effects in an animal model of Parkinson’s disease through central inhibition of the molecular and neurochemical underpinnings of l‐DOPA‐induced dyskinesia. Expand
Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
Compounds targeting specific subtypes of glutamate receptors or calcium channels for their ability to attenuate LID and the associated activation of striatal nuclear signaling and gene expression in the rat are compared. Expand
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
It is concluded that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and represents a good candidate for antidyskinetic treatment in Parkinson's disease. Expand
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
Preclinical data have shown how these drugs act via two different, but interconnected, pathological pathways, and that their complementary activity may produce greater effects than either drug individually. Expand
Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia
In rats that developed dyskinesia, GABA neurons had an increased transcriptional activity, and genes involved in Ca2+ homeostasis, inCa2+ -dependent signaling, and in structural and synaptic plasticity were upregulated. Expand
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
The results of the present study suggest that either subtype of group I of mGluRs may be involved in the pathologically altered circuitry in the basal ganglia, but the equivocal results do not strongly support the hypothesis thatmGluR1 and mGLUR5 antagonists may be beneficial in the symptomatic treatment of Parkinson's disease. Expand
Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats
The data indicate that tolerance does not develop to the anxiolytic and antidyskinetic effects of mGluR5 antagonist MTEP at least at the used treatment mode and tested doses, and also no tolerance to the memory impairing effect of MTEP was observed. Expand
Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies
This in vivo study investigated whether the N‐methyl‐d‐aspartate receptor antagonist, memantine (MEM), interacts with inhibition of acetylcholinesterase (AChE) by reversible (donepezil andExpand
Proteomic analysis of striatal proteins in the rat model of l‐DOPA‐induced dyskinesia
This study investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6‐hydroxydopamine‐lesion rat model of PD treated with saline, l‐DOPA or bromocriptine using two‐dimensional difference gel electrophoresis and mass spectrometry. Expand